WO2012115286A1 - Alpha helix mimetics and methods relating thereto - Google Patents

Alpha helix mimetics and methods relating thereto Download PDF

Info

Publication number
WO2012115286A1
WO2012115286A1 PCT/JP2012/055489 JP2012055489W WO2012115286A1 WO 2012115286 A1 WO2012115286 A1 WO 2012115286A1 JP 2012055489 W JP2012055489 W JP 2012055489W WO 2012115286 A1 WO2012115286 A1 WO 2012115286A1
Authority
WO
WIPO (PCT)
Prior art keywords
optionally substituted
methyl
pyrazino
ylmethyl
benzylcarbamoyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2012/055489
Other languages
English (en)
French (fr)
Inventor
Hiroyuki Kouji
Takenao Odagami
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PRISM BioLab Corp
Original Assignee
PRISM BioLab Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PRISM BioLab Corp filed Critical PRISM BioLab Corp
Priority to EP12710567.4A priority Critical patent/EP2678341A1/en
Priority to US14/001,470 priority patent/US20140051706A1/en
Priority to JP2013539024A priority patent/JP2014509298A/ja
Priority to CN201280010189.1A priority patent/CN103517904A/zh
Publication of WO2012115286A1 publication Critical patent/WO2012115286A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Definitions

  • the present invention relates generally to alpha-helix mimetic structures and to a compound relating thereto.
  • the invention also relates to applications in the treatment of medical conditions, e.g., cancer diseases, fibrotic diseases, and pharmaceutical compositions comprising the mimetics.
  • Odagami et al. disclosed new conformationally constrained compounds which mimic the secondary structure of alpha-helix regions of biologically active peptide and proteins in WO2009/148192, WO2010/044485 and WO2010/128685.
  • the present invention also fulfills these needs, and provides further related advantages by providing
  • Wnt signaling pathway regulates a variety of processes including cell growth, oncogenesis, and development (Moon et al., 1997, Trends Genet. 13, 157-162; Miller et al., 1999,
  • Wnt signaling pathway has been intensely studied in a variety of organisms. The activation of TCF4/ ⁇ catenin mediated transcription by Wnt signal
  • tumor suppressor gene adenomatous polyposis coli APC
  • APC tumor suppressor gene adenomatous polyposis coli
  • GSK serine kinase glycogen synthase kinase
  • ⁇ - catenin Su et al . , 1993, Science 262, 1734-1737: Yost et al., 1996 Genes Dev. 10, 1443-1454: Hayashi et al . , 1997, Proc.
  • LEF1 T-cell factor 4 family of transcription factors
  • c-myc a known oncogene, was shown to be a target gene for ⁇ -catenin/TCF4-mediated transcription (He et al., 1998 Science 281 1509-1512: Kolligs et al . , 1999 Mol .
  • APC tumor suppressor gene
  • CBP CREB binding proteins
  • CBP/p300 potentiates ⁇ -catenin-mediated activation of the siamois promoter, a known Wnt target (Hecht et al, 2000, EMBO J. 19, 8, 1839-1850) .
  • ⁇ -catenin interacts directly with the CREB-binding domain of CBP and ⁇ -catenin synergizes with CBP to stimulate the transcriptional activation of TCF4 ⁇ - catenin (Ken-Ichi Takemaru and Randall T. Moon, 2000 J. Cell. Biol. , 149, 2, 249-254) .
  • the present invention relates generally to alpha-helix mimetic . structures and to a compound relating thereto.
  • the invention also relates to applications in the treatment of medical conditions, e.g., cancer diseases, fibrotic diseases, and pharmaceutical compositions comprising the mimetics.
  • TCF4 ⁇ -catenin and CBP complex of Wnt pathway can be taken as target molecules for the regulation of cell growth
  • the present invention also addresses a need for compounds that block TCF4 ⁇ -catenin transcriptional pathway by inhibiting CBP, and therefore can be used for treatment of cancer, especially colorectal cancer, and fibrotic diseases.
  • the present invention is directed to a new type of
  • This invention also discloses libraries containing such compounds, as well as the synthesis and screening thereof.
  • Another embodiment of the present invention is to provide a prodrug of said alpha-helix mimetics in an attempt to improve oral, bioavailability.
  • the present invention includes the following embodiments.
  • R 71 is optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally
  • R 72 and R 73 are independently selected from hydrogen or halogen;
  • R 74 is a bond or optionally substituted lower alkylene;
  • R 75 is -0-, -(CO)-, -(CO)-O-, or -0-(C0)-0-;
  • R 75 is -(CO) - or - (CO) -0- ;
  • G is -NH-, -NR 6 -, -0-, -CH 2 ⁇ , -CHR 6 - or -C(R 6 ) 2 -, wherein R 6 is independently selected from optionally substituted alkyl, optionally substituted alkenyl and optionally substituted alkynyl;
  • R 1 is optionally substituted arylalkyl, optionally substituted heteroarylalkyl, optionally substituted cycloalkylalkyl or optionally substitut ⁇ d heterocycloalkylalkyl;
  • R 2 is -W 21 -W 22 -Rb-R 20 , wherein W 21 is -(CO) - or -(S0 2 )-; W 22 is a bond, -0-, -NH- or optionally substituted lower alkylene; Rb is a bond or optionally substituted lower alkylene; and R 20 is optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl or optionally substituted heterocycloalkyl; . and R 3 is hydrogen, optionally substituted alkyl, optionally substituted alkenyl or optionally substituted alkynyl;
  • R 75 is- (CO)-.
  • R 74 is a bond
  • R 75 is -(CO)-O-.
  • R 74 is optionally substituted lower alkylene
  • R 75 is -0-.
  • R 74 is optionally substituted lower alkylene
  • R 75 is -0- (CO) -0-.
  • G is -NH-, -NR 6 -, -0-, or -CH 2 -; wherein R 6 is independently selected from optionally substituted alkyl, optionally substituted alkenyl and optionally substituted alkynyl,
  • R 1 is -Ra-R 10 ; wherein Ra is optionally substituted lower alkylene and R 10 is optionally substituted aryl or optionally substituted heteroaryl.
  • R 71 is optionally substituted alkyl or optionally substituted amino acid moiety.
  • R 2 is -W 21 -W 22 -Rb-R 20 , wherein W 21 is -(CO)-; W 22 is -NH- Rb is a bond or optionally substituted lower alkylene; and R 2 is optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl or optionally substituted heterocycloalkyl .
  • R 2 is -W 21 - 22 -Rb-R 20 , wherein W 21 is -(CO)-; W 22 is -NH-; Rb is a bond or optionally substituted lower alkylene; and R 20 is optionally substituted aryl, or optionally substituted heteroaryl.
  • R 3 is hydorogen or C1-4 alkyl.
  • R 71 is optionally substituted Ci-20 alkyl or optionally substituted amino acid moiety
  • R 72 and R 73 are hydrogen.
  • R 71 is Ci-20 alkyl or optionally substituted amino acid moiety
  • R 72 and R 73 are hydrogen.
  • G is -NR 6 - wherein R 6 is lower alkyl or lower alkenyl.
  • G is -C3 ⁇ 4-.
  • Ra is optionally substituted lower alkylene
  • R 10 is optionally substituted benzhydryl, optionally
  • optionally substituted pyridyl optionally substituted pyrimidyl, optionally substituted pyridazinyl, optionally substituted pyrazinyl, optionally substituted triazinyl, optionally substituted pyrrolyl, optionally substituted thienyl, optionally substituted furanyl, optionally
  • substituted thiazolyl optionally substituted oxazolyl, optionally substituted imidazolyl, optionally substituted naphthyl, optionally substituted quinolinyl, optionally
  • pyridopyrimidinyl optionally substituted pyridopyrazinyl, optionally substituted pyridopyridazinyl, optionally
  • substituted pyridotriazinyl optionally substituted indenyl, optionally substituted benzofuryl, optionally substituted benzothienyl, optionally substituted indolyl, optionally substituted indazolyl, optionally substituted benzoxazolyl, optionally substituted benzimidazolyl, optionally substituted benzothiazolyl, optionally substituted benzothiadiazolyl, optionally substituted furopyridinyl, optionally substituted thienopyridinyl, optionally substituted pyrropyridinyl,
  • Ra is optionally substituted lower alkylene
  • R 10 is optionally substituted benzhydryl, optionally
  • pyrimidyl optionally substituted pyridazinyl, optionally substituted pyrazinyl, optionally substituted triazinyl, optionally substituted pyrrolyl, optionally substituted
  • pyridopyrimidinyl optionally substituted pyridopyrazinyl, optionally substituted pyridopyridazinyl, optionally
  • substituted pyridotriazinyl optionally substituted indenyl, optionally substituted benzofuryl, optionally substituted benzothienyl, optionally substituted indolyl, optionally substituted indazolyl, optionally substituted benzoxazolyl, optionally substituted benzimidazolyl, optionally substituted benzothiazolyl, optionally substituted benzothiadiazolyl, optionally substituted f.uropyridinyl, optionally substituted thienopyridinyl optionally substituted pyrropyridinyl,
  • R 3 is hydrogen, or C1- alkyl.
  • R 2 is—W 21 -W 22 -Rb-R 20 , wherein W 21 is -(CO)-; W 22 is -NH-; Rb is a bond or optionally substituted lower alkylene; and R 20 is optionally substituted aryl or optionally substituted
  • R 71 is optionally substituted alkyl or optionally
  • R 72 and R 73 are hydrogen
  • R 1 is -Ra-R 10 ; wherein Ra is optionally substituted lower
  • R 10 is optionally substituted benzhydryl
  • pyrimidyl optionally substituted pyridazinyl, optionally substituted pyrazinyl, optionally substituted triazinyl, optionally substituted pyrrolyl, optionally substituted
  • pyridopyrimidinyl optionally substituted pyridopyrazinyl, optionally substituted pyridopyridazinyl, optionally substituted pyridotriazinyl, optionally substituted indenyl, optionally substituted behzofuryl, optionally substituted benzothienyl, optionally substituted indolyl, optionally substituted indazolyl, optionally substituted benzoxazolyl, optionally substituted benzimidazolyl, optionally substituted benzothiazolyl, optionally substituted benzothiadiazolyl, optionally substituted furopyridinyl, optionally substituted thienopyridinyl, optionally substituted pyrropyridinyl,
  • R 3 is hydrogen or Ci- 4 alkyl
  • R 2 is -W 21 -W 22 -Rb- R 20 , wherein W 21 is -(CO)-; W 22 is -NH-; Rb is a bond or
  • R 20 is optionally substituted lower alkylene
  • R 71 is optionally substituted alkyl or optionally substituted amino acid moiety
  • R 72 and R 73 are hydrogen
  • R 1 is -Ra-R 10 ; wherein Ra is optionally substituted lower alkylene and R 10 is optionally substituted benzhydryl,
  • pyrimidyl optionally substituted pyridazinyl, optionally substituted pyrazinyl, optionally substituted triazinyl, optionally substituted pyrrolyl, optionally substituted
  • pyridopyrimidinyl optionally substituted pyridopyrazinyl, optionally substituted pyridopyridazinyl, optionally
  • substituted pyridotriazinyl optionally substituted indenyl, optionally substituted benzofuryl, optionally substituted benzothienyl, optionally substituted indolyl, optionally substituted indazolyl, optionally substituted benzoxazolyl, optionally substituted benzimidazolyl, optionally substituted benzothiazolyl, optionally substituted benzothiadiazolyl, optionally substituted furopyridinyl, optionally substituted thienopyridinyl, optionally substituted pyrropyridinyl,
  • R 3 is ' Ci- 4 alkyl
  • R 2 is - 21 -W 22 -Rb-R 20 , wherein W 21 is -(CO)-; W 22 is -NH-; Rb is a bond or optionally
  • R 20 is optionally substituted aryl or optionally substituted heteroaryl.
  • R 71 is optionally substituted alkyl or optionally
  • R 72 and R 73 are hydrogen
  • R 1 is -Ra-R 10 ; wherein Ra is optionally substituted lower
  • alkylene and R 10 is optionally substituted benzhydryl
  • optionally substituted biphenyl optionally substituted phenyl, optionally substituted pyridyl, optionally substituted .
  • pyrimidyl optionally substituted pyridazinyl, optionally substituted pyrazinyl, optionally substituted triazinyl, optionally substituted pyrrolyl, optionally substituted
  • pyridopyrimidinyl optionally substituted pyridopyrazinyl, optionally substituted pyridopyridazinyl, optionally
  • R 3 is Ci-4 alkyl
  • R 2 is -W 21 -W 22 -Rb-R 20 , wherein W 21 is -(CO)-; W 22 is -NH-; Rb is a bond or optionally substituted lower alkylene; R 20 is
  • R 71 is optionally substituted alkyl or optionally
  • R 72 and R 73 are hydrogen
  • R 1 is -Ra-R 10 ; wherein Ra is optionally substituted lower alkylene and R 10 is optionally substituted benzhydryl,
  • pyrimidyl optionally substituted pyridazinyl, optionally substituted pyrazinyl, optionally substituted triazinyl, optionally substituted pyrrolyl, optionally substituted
  • pyridopyrimidinyl optionally substituted pyridopyrazinyl, optionally substituted pyridopyridazinyl, optionally
  • substituted pyridotriazinyl optionally substituted indenyl, optionally substituted benzofuryl, optionally substituted benzothienyl, optionally substituted indolyl, optionally
  • R 3 is Ci-4 alkyl
  • R 2 is -W 21 -W 22 -Rb-R 20 , wherein W 21 is -(CO)-; W 22 is -NH-; Rb is a bond or optionally substituted lower alkylene; R 20 is
  • R 71 is optionally substituted alkyl or optionally substituted amino acid moiety
  • R 72 and R 73 are hydrogen
  • R 1 is -Ra-R 10 ; wherein Ra is optionally substituted lower alkylene and R 10 is optionally substituted naphthyl, optionally substituted quinolinyl, optionally substituted isoquinolinyl, optionally substituted quinazolinyl , optionally substituted quinoxalinyl, optionally substituted cinnolinyl, optionally substituted naphthyridinyl, optionally substituted
  • R 3 is Ci-4 alkyl
  • R 2 is -W 21 -W 22 -Rb-R 20 , wherein W 21 is -(CO)-; W 22 is -NH-; Rb is a bond or optionally substituted lower alkylene; R 20 is
  • R 71 is optionally substituted alkyl or optionally substituted amino acid moiety
  • R 72 and R 73 are hydrogen
  • R 1 is -Ra-R 10 ; wherein Ra is optionally substituted lower alkylene and R 10 is optionally substituted naphthyl, optionally substituted quinolinyl, optionally substituted isoquinolinyl, optionally substituted quinazolinyl, optionally substituted quinoxalinyl, .optionally substituted cinnolinyl, optionally substituted naphthyridinyl, optionally substituted
  • R 3 is Ci-4 alkyl
  • R 2 is -W 21 -W 22 -Rb-R 20 , wherein W 21 is -(CO)-; W 22 is -NH-; Rb is a bond or optionally substituted lower alkylene; R 20 is
  • R 71 is optionally substituted Ci-20 alkyl or optionally substituted amino acid moiety
  • R 72 and R 73 are hydrogen
  • R 1 is -Ra-R 10 ; wherein Ra is optionally substituted lower alkylene and R 10 is optionally substituted naphthyl, optionally substituted quinolinyl, optionally substituted isoquinolinyl, optionally substituted quinazolinyl , optionally substituted quinoxalinyl, optionally substituted cinnolinyl, optionally substituted naphthyridinyl, optionally substituted
  • R 3 is Ci- 4 alkyl
  • R 2 is -W 21 -W 22 -Rb-R 20 , wherein W 21 is -(CO)-; W 22 is -NH-; Rb is a bond or optionally
  • R 20 is optionally substituted aryl or optionally substituted heteroaryl .
  • R 71 is optionally substituted Ci- 2 o alkyl or optionally substituted amino acid moiety
  • R 72 and R 73 are hydrogen
  • R 1 is -Ra-R 10 ; wherein Ra is optionally substituted lower alkylene and R 10 is optionally substituted benzhydryl,
  • pyrimidyl optionally substituted pyridazinyl, optionally substituted pyrazinyl, optionally substituted triazinyl, optionally substituted pyrrolyl, optionally substituted
  • substituted pyridotriazinyl optionally substituted indenyl, optionally substituted benzofuryl, optionally substituted benzothienyl, optionally substituted indolyl, optionally substituted indazolyl, optionally substituted benzoxazolyl, optionally substituted benzimidazolyl, optionally substituted benzothiazolyl, optionally substituted benzothiadiazolyl, optionally substituted furopyridinyl, optionally substituted thienopyridinyl, optionally substituted pyrropyridinyl,
  • R 3 is Ci-4 alkyl
  • R 2 is -W 21 -W 22 -Rb-R 20 , wherein W 21 is -(CO)-; W 22 is -NH-; Rb is a bond or optionally substituted lower alkylene; R 20 is
  • R 71 is optionally substituted Ci-20 alkyl or optionally substituted amino acid moiety
  • R 72 and R 73 are hydrogen
  • R 1 is -Ra-R 10 ; wherein Ra is optionally substituted lower alkylene and R 10 is optionally substituted benzhydryl,
  • pyrimidyl optionally substituted pyridazinyl, optionally substituted pyrazinyl, optionally substituted triazinyl, optionally substituted pyrrolyl, optionally substituted
  • substituted pyridotriazinyl optionally substituted indenyl, optionally substituted benzofuryl, optionally substituted benzothienyl, optionally substituted indolyl, optionally
  • R 3 is Ci-4 alkyl
  • R 2 is -W 21 -W 22 -Rb-R 20 , wherein W 21 is -(CO)-; W 22 is -NH-; Rb is a bond or optionally substituted lower alkylene; R 20 is
  • R 71 is optionally substituted Ci-20 alkyl or optionally substituted amino acid moiety
  • R 72 and R 73 are hydrogen
  • R 1 is -Ra-R 10 ; wherein Ra is optionally substituted lower
  • R 10 is optionally substituted benzhydryl
  • pyrimidyl optionally substituted pyridazinyl, optionally substituted pyrazinyl, optionally substituted triazinyl, optionally substituted pyrrolyl, optionally substituted
  • pyridopyrimidinyl optionally substituted pyridopyrazinyl, optionally substituted pyridopyridazinyl, optionally substituted pyridotriazinyl, optionally substituted indenyl, optionally substituted benzofuryl, optionally substituted benzothienyl, optionally substituted indolyl, optionally substituted indazolyl, optionally substituted benzoxazolyl, optionally substituted benzimidazolyl, optionally substituted benzothiazolyl, optionally substituted benzothiadiazolyl, optionally substituted furopyridinyl, optionally substituted thienopyridinyl, optionally substituted pyrropyridinyl,
  • R 3 is Ci-4 alkyl
  • R 2 is -W 21 -W 22 -Rb-R 20 , wherein W 21 is - (CO)-; W 22 is -NH-; Rb is a bond or optionally substituted lower alkylene; R 20 is
  • R 71 is Ci- 2 o alkyl or optionally substituted amino acid moiety
  • R 72 and R 73 are hydrogen
  • R 1 is -Ra-R 10 ; wherein Ra is optionally substituted lower ;
  • R 10 is optionally substituted benzhydryl
  • pyrimidyl optionally substituted pyridazinyl, optionally substituted pyrazinyl, optionally substituted triazinyl, optionally substituted pyrrolyl, optionally substituted
  • pyridopyrim ' idinyl optionally substituted pyridopyrazinyl, optionally substituted pyridopyridazinyl, optionally substituted pyridotriazinyl, optionally substituted indenyl, optionally substituted benzofuryl, optionally substituted benzothienyl, optionally substituted indolyl, optionally substituted indazolyl, optionally substituted benzoxazolyl, optionally substituted benzimidazolyl, optionally substituted benzothiazolyl, optionally substituted benzothiadiazolyl, optionally substituted furopyridinyl, optionally substituted thienopyridinyl, optionally substituted pyrropyridinyl,
  • R 3 is Ci- 4 alkyl
  • R 2 is -W 21 -W 22 -Rb-R 20 , wherein W 21 is -(CO)-; W 22 is -NH-; Rb is a bond or optionally substituted lower alkylene; R 20 is
  • R 71 is Ci- 2 o alkyl or optionally substituted amino acid moiety
  • R 72 and R 73 are hydrogen
  • R 1 is -Ra-R 10 ; wherein Ra is optionally substituted lower alkylene and R 10 is optionally . substituted benzhydryl,.
  • pyrimidyl optionally substituted pyridazinyl, optionally substituted pyrazinyl, optionally substituted triazinyl, optionally substituted pyrrolyl, optionally substituted
  • pyridopyrimidinyl optionally substituted pyridopyrazinyl, optionally substituted pyridopyridazinyl, optionally
  • substituted pyridotriazinyl optionally substituted indenyl, optionally substituted benzofuryl, optionally substituted benzothienyl, optionally substituted indolyl, optionally substituted indazolyl, optionally substituted benzoxazolyl, optionally substituted benzimidazolyl, optionally substituted benzothiazolyl, optionally substituted benzothiadiazolyl, optionally substituted furopyridinyl, optionally substituted thienopyridinyl, optionally substituted pyrropyridinyl,
  • R 3 is Ci_ 4 alkyl
  • R 2 is -W 21 -W 22 -Rb-R 20 ,
  • R 71 is Ci_ 2 o alkyl or optionally substituted amino acid moiety
  • R 72 and R 73 are hydrogen
  • R 1 is -Ra-R 10 ; wherein Ra is optionally substituted lower alkylene and R 10 is optionally substituted benzhydryl,
  • pyrimidyl optionally substituted pyridazinyl, optionally substituted pyrazinyl, optionally substituted triazinyl, optionally substituted pyrrolyl, optionally substituted
  • pyridopyrimidinyl optionally substituted pyridopyrazinyl , optionally substituted pyridopyridazinyl , optionally
  • substituted pyridotriazinyl optionally substituted indenyl, optionally substituted benzofuryl, .
  • optionally substituted benzothienyl optionally substituted indolyl, optionally substituted indazolyl, optionally substituted benzoxazolyl, optionally substituted benzimidazolyl, optionally substituted benzothiazolyl, optionally substituted benzothiadiazolyl, optionally substituted furopyridinyl, optionally substituted thienopyridinyl, optionally substituted pyrropyridinyl, optionally substituted oxazolopyridinyl, optionally
  • R 3 is Ci-4 alkyl
  • R 2 is -W 21 -W 22 -Rb-R 20 , wherein W 21 is -(CO)-; W 22 is -NH-; Rb is a bond or optionally substituted lower alkylene; R 20 is
  • R 71 is Ci-20 alkyl or optionally substituted amino acid moiety
  • R 72 and R 73 are hydrogen
  • R 1 is -Ra-R 10 ; wherein Ra is optionally substituted lower alkylene and R 10 is optionally substituted naphthyl, optionally substituted quinolinyl, optionally substituted isoquinolinyl, optionally substituted quinazolinyl, optionally substituted quinoxalinyl, optionally substituted cinnolinyl, optionally substituted naphthyridinyl, optionally substituted
  • R 3 is Ci-4 alkyl
  • R 2 is -W 21 -W 2 -Rb-R 20 , wherein W 21 is - (CO)-; W 22 is -NH-; Rb is a bond or optionally substituted lower alkylene; R 20 is.
  • R 71 is Ci_ 2 o alkyl or optionally substituted amino acid moiety
  • R 72 and R 73 are hydrogen
  • R 1 is -Ra-R 10 ; wherein Ra is optionally substituted lower alkylene and R 10 is optionally substituted naphthyl, optionally substituted quinolinyl, optionally substituted isoquinolinyl, optionally substituted quinazolinyl, optionally substituted ⁇ quinoxalinyl, optionally substituted cinnolinyl, optionally substituted naphthyridinyl, optionally substituted
  • R 3 is Ci-4 alkyl
  • R 2 is -W 21 -W 22 -Rb-R 20 , wherein W 21 is -(CO)-; W 22 is -NH-; Rb is a bond or optionally substituted lower alkylene; R 20 is
  • R 71 is Ci_ 2 o alkyl or optionally substituted amino acid moiety
  • R 72 and R 73 are hydrogen
  • R 1 is -Ra-R 10 ; wherein Ra is optionally substituted lower alkylene and R 10 is optionally substituted naphthyl, optionally substituted quinolinyl, optionally substituted isoquinolinyl, optionally substituted quinazolinyl, optionally substituted quinoxalinyl, optionally substituted cinnolinyl, optionally substituted naphthyridinyl, optionally substituted
  • R 3 is Ci-4 alkyl
  • R 2 is -W 21 -W 22 -Rb-R 20 , wherein W 21 is -(CO)-; W 22 is -NH-; Rb is a bond or optionally substituted lower alkylene; R 20 is
  • G is -NH-, or -0-; wherein R 6 is independently selected from, optionally substituted alkyl, optionally substituted alkenyl and optionally substituted alkynyl;
  • R 71 is optionally substituted alkyl or optionally substituted amino acid moiety
  • R 72 and R 73 are hydrogen
  • R 1 is -Ra-R 10 ; wherein Ra is optionally substituted lower alkylene and R 10 is optionally substituted benzhydryl,
  • pyrimidyl optionally substituted pyridazinyl, optionally substituted pyrazinyl, optionally substituted triazinyl, optionally substituted pyrrolyl, optionally substituted thienyl, optionally substituted furanyl, optionally substituted thiazolyl, optionally substituted oxazolyl,
  • pyridopyrimidinyl optionally substituted pyridopyrazinyl , optionally substituted pyridopyridazinyl, optionally
  • substituted pyridotriazinyl optionally substituted indenyl, optionally substituted benzofuryl, optionally substituted benzothienyl , optionally substituted indolyl, optionally substituted indazolyl, optionally substituted benzoxazolyl, optionally substituted benzimidazolyl, optionally substituted benzothiazolyl, optionally substituted benzothiadiazolyl, optionally substituted furopyridinyl, optionally substituted thienopyridinyl, optionally substituted pyrropyridinyl,
  • R 3 is hydrogen
  • R 2 is -W 21 -W 22 -Rb-R 20 , wherein W 21 is -(CO)-; W 22 is -NH-; Rb is a bond or optionally substituted lower alkylene; R 20 is
  • G is -NH-, or -0-; wherein R 6 is independently selected from optionally substituted alkyl, optionally substituted alkenyl and optionally substituted alkynyl;
  • R 71 is optionally substituted alkyl or optionally substituted amino acid moiety
  • R 72 and R 73 are hydrogen
  • R 1 is -Ra-R 10 ; wherein Ra is optionally substituted lower alkylene and R 10 is optionally substituted naphthyl, optionally substituted quinolinyl, optionally substituted isoquinolinyl, optionally substituted quinazolinyl, optionally substituted quinoxalinyl, optionally substituted cinnoiinyl, optionally substituted naphthyridinyl, optionally substituted benzotriazinyl, optionally substituted pyridopyrimidinyl, optionally substituted pyridopyrazinyl, optionally substituted pyridopyridazinyl, optionally substituted pyridotriazinyl, optionally substituted indenyl, optionally substituted
  • R 3 is hydrogen
  • R 2 is -W 21 -W 22 -Rb-R 20 , wherein W 21 is -(CO)-; W 22 is -NH-; Rb is a bond or optionally substituted lower alkylene; R 20 is
  • G is -NH-, or -0-; wherein R 6 is independently selected from optionally substituted alkyl, optionally substituted alkenyl and optionally substituted alkynyl;
  • R 71 is optionally substituted Ci_ 2 o alkyl or optionally
  • R 72 and R 73 are hydrogen
  • R 1 is -Ra-R 10 ; wherein Ra is optionally substituted lower alkylene and R 10 is optionally substituted benzhydryl,
  • pyrimidyl optionally substituted pyridazinyl, optionally substituted pyrazinyl, optionally substituted triazinyl, optionally substituted pyrrolyl, optionally substituted
  • pyridopyrimidinyl optionally substituted pyridopyrazinyl, optionally substituted pyridopyridazinyl, optionally
  • substituted pyridotriazinyl optionally substituted indenyl, optionally substituted benzofuryl, optionally substituted benzothienyl , optionally substituted indolyl, optionally substituted indazolyl, optionally substituted benzoxazolyl, optionally substituted benzimidazolyl, optionally substituted benzothiazolyl, optionally substituted benzothiadiazolyl, optionally substituted furopyridinyl, optionally substituted thienopyridinyl, optionally substituted pyrropyridinyl,
  • R 3 is hydrogen
  • R 2 is - 21 -W 22 -Rb-R 20 , wherein W 21 is -(CO)-; W 22 is -NH-; Rb is a bond or optionally substituted lower alkylene; R 20 is
  • G is -NH-, or -0-; wherein R 6 is independently selected from optionally substituted alkyl, optionally substituted alkenyl and optionally substituted alkynyl;
  • R 71 is Ci-20 alkyl or optionally substituted amino acid moiety;
  • R 72 and R 73 are hydrogen;
  • R 1 is -Ra-R 10 ; wherein Ra is optionally substituted lower alkylene and R 10 is optionally substituted benzhydryl,
  • pyrimidyl optionally substituted pyridazinyl, optionally substituted pyrazinyl, optionally substituted triazinyl, optionally substituted pyrrolyl, optionally substituted
  • pyridopyrimidinyl optionally substituted pyridopyrazinyl, optionally substituted pyridopyridazinyl, optionally
  • substituted pyridotriazinyl optionally substituted indenyl, optionally substituted benzofuryl, optionally substituted benzothienyl, optionally substituted indolyl, optionally substituted indazolyl, optionally substituted benzoxazolyl, optionally substituted benzimidazolyl, optionally substituted benzothiazolyl, optionally substituted benzothiadiazolyl, optionally substituted furopyridinyl, optionally substituted thienopyridinyl, optionally substituted pyrropyridinyl,
  • R 3 is hydrogen
  • R 2 is - 21 -W 22 -Rb-R 20 , wherein W 21 is -(CO)-; W 22 is -NH-; Rb is a bond or optionally substituted lower alkylene; R 20 is
  • R 71 is Ci- 2 o alkyl or optionally substituted amino acid moiety
  • R 72 and R 73 are hydrogen
  • R 1 is -Ra-R 10 ; wherein Ra is optionally substituted lower
  • R 10 is optionally substituted benzhydryl
  • pyridopyrimidinyl optionally substituted pyridopyrazinyl, optionally substituted pyridopyridazinyl, optionally
  • substituted pyridotriazinyl optionally substituted indenyl, optionally substituted benzofuryl, optionally substituted benzothienyl, optionally . substituted indolyl, optionally
  • R 3 is hydrogen
  • R 2 is -W 21 -W 22 -Rb-R 20 , wherein W 21 is -(CO) -; W 22 is -NH-; Rb is a bond or optionally substituted lower alkylene; R 20 is
  • R 71 is Ci-20 alkyl or optionally substituted amino acid moiety
  • R 72 and R 73 are hydrogen
  • R 1 is -Ra-R 10 ; wherein Ra is optionally substituted lower
  • R 10 is optionally substituted benzhydryl
  • pyrimidyl optionally substituted pyridazinyl, optionally substituted pyrazinyl, optionally substituted triazinyl, .
  • pyridopyrimidinyl optionally substituted pyridopyrazinyl , optionally substituted pyridopyridazinyl, optionally
  • substituted pyridotri ' azinyl optionally substituted indenyl, optionally substituted benzofuryl, optionally substituted benzothienyl, optionally substituted indolyl, optionally substituted indazolyl, optionally substituted benzoxazolyl, optionally substituted benzimidazolyl, optionally substituted benzothiazolyl, optionally substituted benzothiadiazolyl, optionally substituted furopyridinyl , optionally substituted thienopyridinyl, optionally substituted pyrropyridinyl, optionally substituted oxazolopyridinyl, optionally
  • R 3 is hydrogen
  • R 2 is -W 21 -W 22 -Rb-R 20 , wherein W 21 is -(CO)-; 22 is -NH-; Rb is a bond or optionally substituted lower alkylene; R 20 is
  • G is -NH-, or -0-; wherein R 6 is independently selected from optionally substituted alkyl, optionally substituted alkenyl and optionally substituted alkynyl;
  • R 71 is Ci-20 alkyl or optionally substituted amino acid moiety;
  • R 72 and R 73 are hydrogen;
  • R 1 is -Ra-R 10 wherein Ra is optionally substituted lower alkylene and R 10 is optionally substituted naphthyl, optionally substituted quinolinyl, optionally substituted isoquinolinyl, optionally substituted quinazolinyl, optionally substituted quinoxalinyl, optionally substituted cinnolinyl, optionally substituted naphthyridinyl, optionally substituted
  • benzofuryl optionally substituted benzothienyl, optionally substituted indolyl, optionally substituted indazolyl, optionally substituted benzoxazolyl, optionally substituted benzimidazolyl, optionally substituted benzothiazolyl, optionally substituted benzothiadiazolyl, optionally
  • R 3 is hydrogen
  • R 2 is -W 21 -W 22 -Rb-R 20 , wherein W 21 is -(CO)-; W 22 is -NH-; Rb is a bond or optionally substituted lower alkylene; R 20 is
  • R 71 is Ci-20 alkyl or optionally substituted amino acid moiety
  • R 72 and R 73 are hydrogen
  • R 1 is -Ra-R 10 ; wherein Ra is optionally substituted lower alkylene and R 10 is optionally substituted naphthyl, optionally substituted quinolinyl, optionally substituted isoquinolinyl, optionally substituted quinazolinyl, optionally substituted quinoxalinyl, optionally substituted cinnolinyl, optionally substituted naphthyridinyl, optionally substituted
  • R 3 is hydrogen
  • R 2 is -W 21 -W 22 -Rb-R 20 , wherein W 21 is -(CO)-; W 22 is -NH-; Rb is a bond or optionally substituted lower alkylene; R 20 is
  • R 71 is Ci- 2 o alkyl or optionally substituted amino acid moiety
  • R 72 and R 73 are hydrogen
  • R 1 is -Ra ⁇ R 10 ; wherein Ra is optionally substituted lower alkylene and R 10 is optionally substituted naphthyl, optionally substituted quinolinyl, optionally substituted isoquinolinyl, optionally substituted quinazolinyl , optionally substituted quinoxalinyl, optionally substituted cinnolinyl, optionally substituted naphthyridinyl, optionally substituted
  • R 3 is hydrogen
  • R 2 is -W 21 -W 22 -Rb-R 20 , wherein W 21 is -(CO)-; W 22 is -NH-; Rb is a bond or optionally substituted lower alkylene; R 20 is
  • R 71 is optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally
  • R 72 and R 73 are independently selected from hydrogen or halogen;
  • R 74 is a bond or optionally substituted lower alkylene;
  • R 75 is -0-, -(CO)-, -(CO)-O-, or -0- (CO) -0-;
  • R 75 is -(CO) - or .-(CO)-O- r
  • G is -NH-, -NR 6 -, -0-, -CH 2 -, -CHR 6 - or -C(R 6 ) 2 -, wherein R 6 is independently selected from optionally substituted alkyl, optionally substituted alkenyl.and optionally substituted alkynyl;
  • R 1 is optionally substituted arylalkyl, optionally substituted heteroarylalkyl, optionally substituted cycloalkylalkyl or optionally substituted heterocycloalkylalkyl ;
  • R 2 is -W 21 -W 22 -Rb-R 20 , wherein W 21 is -(CO) - or -(S0 2 )-; W 22 is a bond, -0-, -NH- or optionally substituted lower alkylene; Rb is a bond or optionally substituted lower alkylene; and R 20 is optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl or optionally substituted heterocycloalkyl;
  • R 3 is hydrogen, optionally substituted alkyl, optionally substituted alkenyl or optionally substituted alkynyl;
  • R 91 is selected from optionally substituted alkyl, linker or solid support.
  • R 92 is selected from optionally substituted alkyl, linker or solid support; or a salt thereof.
  • R 74 is a bond
  • R 75 is- (CO)-.
  • R 74 is a bond
  • R 75 is - (CO) -0-.
  • R 74 is optionally substituted lower alkylene
  • R 75 is -0-.
  • R 74 is optionally substituted lower alkylene
  • R 75 is -0-(CO)-0-.
  • G is -NH-, -NR 6 -, -0-, or -CH 2 -; wherein R 5 is
  • R 1 is -Ra-R 10 ; wherein Ra is optionally substituted lower alkylene and R 10 is optionally substituted aryl or optionally substituted heteroaryl.
  • R 71 is optionally substituted alkyl.
  • R 2 is -W 21 -W 22 -Rb-R 20 , wherein W 21 is -(CO)-; W 22 is -NH-; Rb is a bond or optionally substituted lower alkylene; and R 20 is optionally substituted aryl, optionally substituted - heteroaryl, optionally substituted cycloalkyl or optionally substituted heterocycloalkyl .
  • R 2 is -W 21 -W 22 -Rb-R 20 , wherein W 21 is -(CO)-; W 22 is -NH-; Rb is a bond or optionally substituted lower alkylene; and R 20 is optionally substituted aryl, or optionally substituted heteroaryl .
  • R 3 is hydorogen or Ci_ 4 alkyl.
  • R 71 is optionally substituted Ci-20 alkyl or optionally substituted amino acid moiety
  • R 72 and R 73 are hydrogen.
  • R 71 is Ci-20 alkyl or optionally substituted amino acid moiety
  • R 72 and R 73 are hydrogen.
  • G is -C3 ⁇ 4-.
  • Ra is optionally substituted lower alkylene
  • R 10 is optionally substituted benzhydryl, optionally
  • pyrimidyl optionally substituted pyridazinyl, optionally substituted pyrazinyl, optionally. substituted triazinyl, optionally substituted pyrrolyl, optionally substituted
  • substituted pyridotriazinyl optionally substituted indenyl, optionally substituted benzofuryl, optionally substituted benzothienyl , optionally substituted indolyl, optionally substituted indazolyl, optionally substituted benzoxazolyl, optionally substituted benzimidazolyl, optionally substituted benzothiazolyl, optionally substituted benzothiadiazolyl,optionally substituted furopyridinyl, optionally substituted thienopyridinyl, optionally substituted pyrropyridinyl,
  • Ra is optionally substituted lower alkylene
  • R 10 is optionally substituted behzhydryl, optionally
  • pyrimidyl optionally substituted pyridazinyl, optionally substituted pyrazinyl, optionally substituted triazinyl, optionally substituted pyrrolyl, optionally substituted
  • pyridopyrimidinyl optionally substituted pyridopyrazinyl, optionally substituted pyridopyridazinyl, optionally
  • substituted pyridotriazinyl optionally substituted indenyl, optionally substituted benzofuryl, optionally substituted benzothienyl, optionally substituted indolyl, optionally substituted indazolyl, optionally substituted benzoxazolyl, optionally substituted benzimidazolyl, optionally substituted benzothiazolyl, optionally substituted benzothiadiazolyl, optionally substituted furopyridinyl , optionally substituted thienopyridinyl, optionally substituted pyrropyridinyl,
  • R 3 is hydrogen, or Ci_ 4 alkyl.
  • R 2 is -W 21 -W 22 -Rb-R 20 , wherein W 21 is -(CO)-; W 22 is -NH-; Rb is a bond or optionally substituted lower alkylene; and R 20 is optionally substituted aryl or optionally substituted heteroaryl.
  • R 71 is optionally substituted alkyl or optionally
  • R 72 and R 73 are hydrogen
  • R 1 is -Ra-R 10 ; wherein Ra is optionally substituted' lower alkylene and R 10 is optionally substituted benzhydryl,
  • pyrimidyl optionally substituted pyridazinyl, optionally substituted pyrazinyl, optionally substituted triazinyl, optionally substituted pyrrolyl, optionally substituted
  • pyridopyrimidinyl optionally substituted pyridopyrazinyl, optionally substituted pyridopyridazinyl , optionally
  • substituted pyridotriazinyl optionally substituted indenyl, optionally substituted benzofuryl, optionally substituted benzothienyl , optionally substituted indolyl, optionally substituted indazolyl, optionally substituted benzoxazolyl, optionally substituted benzimidazolyl, optionally substituted benzothiazolyl, optionally substituted benzothiadiazolyl, optionally substituted furopyridinyl, optionally substituted thienopyridinyl, optionally substituted pyrropyridinyl,
  • R 3 is hydrogen or C1-4 alkyl
  • R 2 is -W 21 -W 22 - Rb-R 20 , wherein W 21 is -(CO)-; W 22 is -NH-; Rb is a bond or optionally substituted lower alkylene; R 20 is optionally
  • R 71 is optionally substituted alkyl or optionally
  • R 1 is -Ra-R 10 ; wherein Ra is optionally substituted lower
  • R 10 is optionally substituted benzhydryl
  • pyrimidyl optionally substituted pyridazinyl, optionally substituted pyrazinyl, optionally substituted triazinyl, optionally substituted pyrrolyl, optionally substituted
  • pyridopyrimidinyl optionally substituted pyridopyrazinyl , optionally substituted pyridopyridazinyl, optionally
  • substituted pyridotriazinyl optionally substituted indenyl, optionally substituted benzofuryl, optionally substituted benzothienyl, optionally substituted indolyl, optionally
  • R 3 is Ci_ 4 alkyl
  • R 2 is- -W 21 -W 22 -Rb-R 20 ,
  • R 71 is optionally substituted alkyl or optionally
  • R 72 and R 73 are hydrogen
  • R 1 is -Ra-R 10 ; wherein Ra is optionally substituted lower
  • R 10 is optionally substituted benzhydryl
  • pyrimidyl optionally substituted pyridazinyl, optionally substituted pyrazinyl, optionally substituted triazinyl, optionally substituted pyrrolyl, optionally substituted
  • substituted isoquinolinyl optionally substituted quinazolinyl, optionally substituted quinoxalinyl , optionally substituted cinnolinyl, optionally substituted naphthyridinyl, optionally substituted benzotriazinyl, optionally substituted
  • pyridopyrimidinyl optionally substituted pyridopyrazinyl , optionally substituted pyridopyridazinyl, optionally
  • substituted pyridotriazinyl optionally substituted indenyl, optionally substituted benzofuryl, optionally substituted benzothienyl, optionally substituted indolyl, optionally
  • R 3 is Ci-4 alkyl
  • R 2 is -W 21 -W 22 -Rb-R 20 , wherein W 21 is -(CO)-; W 22 is -NH-; Rb is a bond or optionally substituted lower alkylene R 20 is
  • R 71 is optionally substituted alkyl or optionally substituted amino acid moiety
  • R 72 and R 73 are hydrogen
  • R 1 is -Ra-R 10 ; wherein Ra is optionally substituted lower alkylene and R 10 is optionally substituted benzhydryl,
  • pyrimidyl optionally substituted pyridazinyl, optionally substituted pyrazinyl, optionally substituted triazinyl, optionally substituted pyrrolyl, optionally substituted
  • pyridopyrimidinyl optionally substituted pyridopyrazinyl, optionally substituted pyridopyridazinyl, optionally
  • substituted pyridotriazinyl optionally substituted indenyl, optionally substituted benzofuryl, optionally substituted benzothienyl, optionally substituted indolyl, optionally substituted indazolyl, optionally substituted benzoxazolyl, optionally substituted benzimidazolyl, optionally substituted benzothiazolyl, optionally substituted benzothiadiazolyl, optionally substituted furopyridinyl, optionally substituted thienopyridinyl, optionally substituted pyrropyridinyl,
  • R 3 is Ci-4 alkyl
  • R 2 is -W 21 -W 22 -Rb-R 20 , wherein W 21 is -(CO)-; W 22 is -NH-; Rb is a bond or optionally substituted lower alkylene; R 20 is
  • R 71 is optionally substituted alkyl or optionally substituted amino acid moiety
  • R 72 and R 73 are hydrogen
  • R 1 is -Ra-R 10 ; wherein Ra is optionally substituted lower alkylene and R 10 is optionally substituted naphthyl, optionally substituted quinolinyl, optionally substituted isoquinolinyl, optionally substituted quinazolinyl , optionally substituted quinoxalinyl, optionally substituted cinnolinyl, optionally substituted naphthyridinyl, optionally substituted
  • R 3 is Ci-4 alkyl
  • R 2 is -W 21 -W 22 -Rb-R 20 , wherein 21 is - (CO)-; W 22 is -NH-; Rb is a bond or optionally substituted lower alkylene; R 20 is
  • R 71 is optionally substituted alkyl or optionally substituted amino acid moiety;
  • R 72 and R 73 are hydrogen
  • R 1 is -Ra-R 10 ; wherein Ra is optionally substituted lower alkylene and R 10 is optionally substituted naphthyl, optionally substituted quinolinyl, optionally substituted isoquinolinyl, optionally substituted quinazolinyl, optionally substituted quinoxalinyl, optionally substituted cinnolinyl, optionally substituted naphthyridinyl, optionally substituted
  • R 3 is Ci-4 alkyl
  • R 2 is -W 21 - 22 -Rb-R 20 , wherein W 21 is -(CO)-; W 22 is -NH-; Rb is a bond or optionally substituted lower alkylene; R 20 is
  • R 71 is optionally substituted Ci-20 alkyl or optionally substituted amino acid moiety
  • R 72 and R 73 are hydrogen
  • R 1 is -Ra-R 10 ; wherein Ra is optionally substituted lower alkylene and R 10 is optionally substituted naphthyl, optionally substituted quinolinyl, optionally substituted isoquinolinyl, optionally substituted quinazolinyl, optionally substituted quinoxalinyl, optionally substituted cinnolinyl, optionally substituted naphthyridinyl, optionally subs ' tituted
  • R 3 is Ci_ 4 alkyl
  • R 2 is - 21 -W 22 -Rb-R 20 ,
  • R 71 is optionally substituted Ci-20 alkyl or optionally substituted amino acid moiety
  • R 72 and R 73 are hydrogen
  • R 1 is -Ra-R 10 ; wherein Ra is optionally substituted lower
  • R 10 is optionally substituted benzhydryl
  • substituted pyrazinyl optionally substituted triazinyl, optionally substituted pyrrolyl, optionally substituted
  • substituted isoquinolinyl optionally substituted quinazoiinyl, optionally substituted quinoxalinyl, optionally substituted cinnolinyl, optionally substituted naphthyridinyl, optionally substituted benzotriazinyl, optionally substituted
  • pyridopyrimidinyl optionally substituted pyridopyrazinyl , optionally substituted pyridopyridazinyl, optionally
  • substituted pyridotriazinyl optionally substituted indenyl, optionally substituted benzofuryl, optionally substituted benzothienyl, optionally substituted indolyl, optionally substituted indazolyl, optionally substituted benzoxazolyl, optionally substituted benzimidazolyl, optionally substituted benzothiazolyl, optionally substituted benzothiadiazolyl, optionally substituted furopyridinyl, optionally substituted thienopyridinyl, optionally substituted pyrropyridinyl,
  • R 3 is Ci-4 alkyl
  • R 2 is -W 21 -W 22 -Rb-R 20 , wherein W 21 is -(CO)-; W 22 is -NH-; Rb is a bond or optionally substituted lower alkylene; R 20 is
  • R 71 is optionally substituted Ci-20 alkyl or optionally substituted amino acid moiety
  • R 72 and R 73 are hydrogen
  • R 1 is -Ra-R 10 ; wherein Ra is optionally substituted lower alkylene and R 10 is optionally substituted benzhydryl,
  • biphenyl optionally substituted phenyl, optionally substituted pyridyl, optionally substituted
  • pyrimidyl optionally substituted pyridazinyl, optionally substituted pyrazinyl, optionally substituted triazinyl, optionally substituted pyrrolyl, optionally substituted
  • pyridopyrimidinyl optionally substituted pyridopyrazinyl , optionally substituted pyridopyridazinyl, optionally
  • substituted pyridotriazinyl optionally substituted disorder indenyl, optionally substituted benzofuryl, optionally substituted benzothienyl, optionally substituted indolyl, optionally substituted indazolyl, optionally substituted benzoxazolyl, optionally substituted benzimidazolyl, optionally substituted benzothiazolyl, optionally substituted benzothiadiazolyl, optionally substituted furopyridinyl , optionally substituted thienopyridinyl, optionally substituted pyrropyridinyl,
  • R 3 is Ci-4 alkyl
  • R 2 is -W 21 -W 22 -Rb-R 20 , wherein W 21 is -(CO)-; W 22 is -NH-; Rb is a bond or optionally substituted lower alkylene; R 20 is
  • R 71 is optionally substituted Ci- 2 o alkyl or optionally substituted amino acid moiety
  • R 72 and R 73 are hydrogen
  • R 1 is -Ra-R 10 ; wherein Ra is optionally substituted lower alkylene and R 10 is optionally substituted benzhydryl,
  • pyrimidyl optionally substituted pyridazinyl, optionally substituted pyrazinyl, optionally substituted triazinyl, optionally substituted pyrrolyl, optionally substituted
  • pyridopyrimidinyl optionally substituted pyridopyrazinyl , optionally substituted pyridopyridazinyl , optionally
  • substituted pyridotriazinyl optionally substituted indenyl, optionally substituted benzofuryl, optionally substituted benzothienyl, optionally substituted indolyl, optionally substituted indazolyl, optionally substituted benzoxazolyl, optionally substituted benzimidazolyl, optionally substituted benzothiazolyl, optionally substituted benzothiadiazolyl, optionally substituted furopyridinyl, optionally substituted thienopyridinyl, optionally substituted pyrropyridinyl,
  • R 3 is Ci-4 alkyl
  • R 2 is -W 21 -W 22 -Rb-R 20 , wherein W 21 is -(CO)-; W 22 is -NH-; Rb is a bond or optionally substituted lower alkylene; R 20 is
  • R 71 is Ci-20 alkyl or optionally substituted amino acid moiety
  • R 72 and R 73 are hydrogen
  • R 1 is -Ra-R 10 ; wherein Ra is optionally substituted lower alkylene and R 10 is optionally substituted benzhydryl,
  • pyrimidyl optionally substituted pyridazinyl, optionally substituted pyrazinyl, optionally substituted triazinyl, optionally substituted pyrrolyl, optionally substituted
  • pyridopyrimidinyl optionally . substituted pyridopyrazinyl, optionally substituted pyridopyridazinyl, optionally
  • substituted pyridotriazinyl optionally substituted indenyl, optionally substituted benzofuryl, optionally substituted benzothienyl, optionally substituted indolyl, optionally substituted indazolyl, optionally substituted benzoxazolyl, optionally substituted benzimidazolyl, optionally substituted benzothiazolyl,. optionally substituted benzothiadiazolyl, optionally substituted furopyridinyl, optionally substituted thienopyridinyl, optionally substituted p ⁇ yrropyridinyl,
  • R 3 is Ci-4 alkyl
  • R 2 is -W 21 -W 22 -Rb-R 20 , wherein W 21 is - (CO) -; W 22 is -NH-; Rb is a bond or optionally substituted lower alkylene; R 20 is
  • R 71 is C1-20 alkyl or optionally substituted amino acid moiety
  • R 72 and R 73 are hydrogen
  • R 1 is -Ra-R 10 ; wherein Ra is optionally substituted lower alkylene and R 10 is optionally substituted benzhydryl,
  • pyrimidyl optionally substituted pyridazinyl, optionally substituted pyrazinyl, optionally substituted triazinyl, optionally substituted pyrrolyl, optionally substituted
  • pyridopyrimidinyl optionally substituted pyridopyrazinyl, optionally substituted pyridopyridazinyl, optionally
  • substituted pyridotriazinyl optionally substituted indenyl, optionally substituted benzofuryl, optionally substituted benzothienyl, optionally substituted indolyl, optionally substituted indazolyl, optionally substituted benzoxazolyl, optionally substituted benzimidazolyl, optionally substituted benzothiazolyl, optionally substituted benzothiadiazolyl, optionally substituted furopyridinyl, optionally substituted thienopyridinyl, optionally substituted pyrropyridinyl,
  • R 3 is Ci-4 alkyl
  • R 2 is -W 21 - 22 -Rb-R 20 , wherein W 21 is -(CO)-; W 22 is -NH-; Rb is a bond or optionally substituted lower alkylene; R 20 is
  • R 71 is Ci-20 alkyl or optionally substituted amino acid moiety
  • R 72 and R 73 are hydrogen
  • R 1 is -Ra-R 10 ; wherein Ra is optionally substituted lower alkylene and R 10 is optionally substituted benzhydryl,
  • pyrimidyl optionally substituted pyridazinyl, optionally substituted pyrazinyl, optionally substituted triazinyl, optionally substituted pyrrolyl, optionally substituted
  • pyridopyrimidinyl optionally substituted pyridopyrazinyl, optionally substituted pyridopyridazinyl, optionally
  • substituted pyridotriazinyl optionally substituted indenyl, optionally substituted benzofuryl, optionally substituted benzothienyl , optionally substituted indolyl, optionally substituted indazolyl, optionally substituted benzoxazolyl, optionally substituted benzimidazolyl, optionally substituted benzothiazolyl, optionally substituted benzothiadiazolyl, optionally substituted furopyridinyl, optionally substituted thienopyridinyl, optionally substituted pyrropyridinyl, optionally substituted oxazolopyridinyl, optionally
  • R 3 is Ci-4 ⁇ alkyl
  • R 2 is -W 21 -W 22 -Rb-R 20 , wherein W 21 is -(CO)-; W 22 is -NH-; Rb is a bond or optionally substituted lower alkylene; R 20 is
  • R 71 is Ci_ 2 o alkyl or optionally substituted amino acid moiety
  • R 72 and R 73 are hydrogen
  • R 1 is -Ra-R 10 ; wherein Ra is optionally substituted lower alkylene and R 10 is optionally substituted naphthyl, optionally substituted quinolinyl, optionally substituted isoquinolinyl, optionally substituted quinazolinyl , optionally substituted quinoxalinyl, optionally substituted cinnolinyl, optionally substituted naphthyridinyl, optionally substituted
  • R 3 is Ci-4 alkyl
  • R 2 is -W 21 -W 22 -Rb-R 20 , wherein W 21 is -(CO)-; W 22 is -NH-; Rb is a bond or optionally substituted lower alkylene; R 20 is
  • R 71 is Ci-20 alkyl or optionally substituted amino acid moiety
  • R 72 and R 73 are hydrogen
  • R 1 is -Ra-R 10 ; wherein Ra is optionally substituted lower alkylene and R 10 is optionally substituted naphthyl, optionally substituted quinolinyl, optionally substituted isoquinolinyl, optionally substituted quinazolinyl, optionally substituted quinoxalinyl, optionally substituted cinnolinyl, optionally substituted naphthyridinyl, optionally substituted
  • R 3 is Ci-4 alkyl
  • R 2 is -W 21 -W 22 -Rb-R 20 , wherein W 21 is -(CO)-; W 22 is -NH-; Rb is a bond or optionally substituted lower alkylene; R 20 is
  • R 71 is Ci-20 alkyl or optionally substituted amino acid moiety
  • R 72 and R 73 are hydrogen
  • R 1 is -Ra-R 10 ; wherein Ra is optionally substituted lower alkylene and R 10 is optionally substituted naphthyl, optionally substituted quinolinyl, optionally substituted isoquinolinyl, optionally substituted quinazolinyl, optionally substituted quinoxalinyl, optionally substituted cinnolinyl, optionally substituted naphthyridinyl, optionally substituted
  • R 3 is Ci-4 alkyl
  • R 2 is -W 21 -W 22 -Rb-R 20 , wherein W 21 is -(CO)-; W 22 is -NH-; Rb is a bond or optionally substituted lower alkylene; R 20 is
  • G is -NH-, or -0-; wherein R 6 is independently selected from optionally substituted alkyl, optionally substituted alkenyl and optionally substituted alkynyl;
  • R 71 is optionally substituted alkyl or optionally substituted amino acid moiety
  • R 72 and R 73 are hydrogen
  • R 1 is -Ra-R 10 ; wherein Ra is optionally substituted lower
  • R 10 is optionally substituted benzhydryl
  • pyrimidyl optionally substituted pyridazinyl, optionally substituted pyrazinyl, optionally substituted triazinyl, optionally substituted pyrrolyl, optionally substituted
  • pyridopyrimidinyl optionally substituted pyridopyrazinyl, optionally substituted pyridopyridazinyl, optionally
  • substituted pyridotriazinyl optionally substituted indenyl, optionally substituted benzofuryl, optionally substituted benzothienyl, optionally substituted indolyl, optionally substituted indazolyl, optionally substituted benzoxazolyl, optionally substituted benzimidazolyl, optionally substituted benzothiazolyl, optionally substituted benzothiadiazolyl, optionally substituted furopyridinyl, optionally substituted thienopyridinyl, optionally substituted pyrropyridinyl,
  • R 3 is hydrogen
  • R 2 is -W 21 -W 22 -Rb-R 20 , wherein W 21 is -(CO)-; W 22 is -NH-; Rb is a bond or optionally substituted lower alkylene; R 20 is "
  • G is -NH-, -NR 6 -, or -0-; wherein R s is independently selected from- optionally substituted alkyl, optionally
  • R 71 is optionally substituted alkyl or optionally substituted amino acid moiety
  • R 72 and R 73 are hydrogen
  • R 1 is -Ra-R 10 ; wherein Ra is optionally substituted lower alkylene and R 10 is optionally substituted naphthyl, optionally substituted quinolinyl, optionally substituted isoquinolinyl, optionally substituted quinazolinyl, optionally substituted quinoxalinyl, optionally substituted cinnolinyl, optionally - substituted naphthyridinyl, optionally substituted
  • R 3 is hydrogen
  • R 2 is -W 21 -W 22 -Rb-R 20 , wherein W 21 is -(CO)-; W 22 is -NH-; Rb is a bond or optionally substituted lower alkylene; R 20 is
  • G is -NH-, or -0-; wherein R 6 is independently selected from optionally substituted alkyl, optionally substituted alkenyl and optionally substituted alkynyl;
  • R 71 is optionally substituted Ci-20 alkyl or optionally
  • R 72 and R 73 are hydrogen
  • R 1 is -Ra-R 10 ; wherein Ra is optionally substituted lower
  • R 10 is optionally substituted benzhydryl
  • pyrimidyl optionally substituted pyridazinyl, optionally substituted pyrazinyl,. optionally substituted triazinyl, optionally substituted pyrrolyl, optionally substituted
  • substituted pyridotriazinyl optionally substituted indenyl, optionally substituted benzofuryl, optionally substituted benzothienyl , optionally substituted indolyl, optionally substituted indazolyl, optionally substituted benzoxazolyl, optionally substituted benzimidazolyl, optionally substituted benzothiazolyl, optionally substituted benzothiadiazolyl, optionally substituted furopyridinyl, optionally substituted thienopyridinyl, optionally substituted pyrropyridinyl,
  • R 3 is hydrogen
  • R 2 is -W 21 -W 22 -Rb-R 20 , wherein W 21 is -(CO)-; W 22 is -NH-; Rb is a bond or optionally substituted lower alkylene; R 20 is
  • G is -NH-, or -0-; wherein R 6 is independently selected from optionally substituted alkyl, optionally substituted alkenyl and optionally substituted alkynyl;
  • R 71 is Ci-20 alkyl or optionally substituted amino acid moiety; R 72 and R 73 are hydrogen
  • R 1 is -Ra-R 10 ; wherein Ra is optionally substituted lower alkylene and R 10 is optionally substituted benzhydryl,
  • pyrimidyl optionally substituted pyridazinyl, optionally substituted pyrazinyl, optionally substituted triazinyl, optionally substituted pyrrolyl, optionally substituted
  • substituted isoquinolinyl optionally substituted quinazolinyl, optionally substituted quinoxalinyl , optionally substituted cinnolinyl, optionally substituted naphthyridinyl, optionally substituted benzotriazinyl, optionally substituted
  • pyridopyrimidinyl optionally substituted pyridopyrazinyl , . ' optionally substituted pyridopyridazinyl, optionally
  • substituted pyridotriazinyl optionally substituted indenyl, optionally substituted benzofuryl, optionally substituted benzothienyl, optionally substituted indolyl, optionally
  • substituted indazolyl optionally, substituted benzoxazolyl, optionally substituted benzimidazolyl, optionally substituted benzothiazolyl, optionally substituted benzothiadiazolyl, optionally substituted furopyridinyl, optionally substituted thienopyridinyl, optionally substituted pyrropyridinyl,
  • R 3 is hydrogen
  • R 2 is -W 21 -W 22 -Rb-R 20 , wherein W 21 is -(CO)-; W 22 is -NH-; Rb is a bond or optionally substituted lower alkylene; R 20 is
  • R 71 is G1-20 alkyl or optionally substituted amino acid moiety
  • R 72 and R 73 are hydrogen
  • R 1 is -Ra-R 10 ; wherein Ra is optionally substituted lower
  • R 10 is optionally substituted benzhydryl
  • pyrimidyl optionally substituted pyridazinyl, optionally substituted pyrazinyl, optionally substituted triazinyl, optionally substituted pyrrolyl, optionally substituted
  • substituted pyridotriazinyl optionally substituted indenyl, optionally substituted benzofuryl, optionally substituted benzothienyl, optionally substituted indolyl, optionally substituted indazolyl,.
  • optionally substituted benzoxazolyl optionally substituted benzimidazolyl
  • optionally substituted benzothiazolyl optionally substituted benzothiadiazolyl
  • furopyridinyl optionally substituted thienopyridinyl
  • optionally substituted pyrropyridinyl optionally substituted furopyridinyl, optionally substituted thienopyridinyl, optionally substituted pyrropyridinyl
  • R 3 is hydrogen
  • R 2 is -W 21 -W 22 -Rb-R 20 , wherein W 21 is — (CO)-; W 22 is -NH-; Rb is a bond or optionally substituted lower alkylene; R 20 is
  • R 71 is Ci-20 alkyl or optionally substituted amino acid moiety
  • R 72 and R 73 are hydrogen
  • R 1 is -Ra-R 10 ; wherein Ra is optionally substituted lower alkylene and R 10 is optionally substituted benzhydryl,
  • pyrimidyl optionally substituted pyridazinyl, optionally substituted pyrazinyl, optionally substituted triazinyl, optionally substituted pyrrolyl, optionally substituted
  • substituted pyridotriazinyl optionally substituted indenyl, optionally substituted benzofuryl, optionally, substituted benzothienyl, optionally substituted indolyl, optionally substituted indazolyl, optionally substituted benzoxazolyl, optionally substituted benzimidazolyl, optionally substituted benzothiazolyl, optionally substituted benzothiadiazolyl, optionally substituted furopyridinyl, optionally substituted thienopyridinyl, optionally substituted pyrropyridinyl, optionally substituted oxazolopyridinyl, optionally
  • R 3 is hydrogen
  • R 2 is -W 21 -W 22 -Rb-R 20 , wherein W 21 is - (CO)-; W 22 is -NH-; Rb is a bond or optionally substituted lower alkylene; R 20 is

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PCT/JP2012/055489 2011-02-25 2012-02-27 Alpha helix mimetics and methods relating thereto Ceased WO2012115286A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP12710567.4A EP2678341A1 (en) 2011-02-25 2012-02-27 Alpha helix mimetics and methods relating thereto
US14/001,470 US20140051706A1 (en) 2011-02-25 2012-02-27 Alpha helix mimetics and methods relating thereto
JP2013539024A JP2014509298A (ja) 2011-02-25 2012-02-27 アルファへリックスミメティック及びその関連の方法
CN201280010189.1A CN103517904A (zh) 2011-02-25 2012-02-27 α-螺旋模拟物和与其相关的方法

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161446801P 2011-02-25 2011-02-25
US61/446,801 2011-02-25

Publications (1)

Publication Number Publication Date
WO2012115286A1 true WO2012115286A1 (en) 2012-08-30

Family

ID=45878996

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2012/055489 Ceased WO2012115286A1 (en) 2011-02-25 2012-02-27 Alpha helix mimetics and methods relating thereto

Country Status (5)

Country Link
US (1) US20140051706A1 (enExample)
EP (1) EP2678341A1 (enExample)
JP (1) JP2014509298A (enExample)
CN (1) CN103517904A (enExample)
WO (1) WO2012115286A1 (enExample)

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20130140079A (ko) * 2010-11-16 2013-12-23 유니버시티 오브 써던 캘리포니아 체세포 줄기 세포의 비대칭 분열을 향상시키기 위한 ｃｂｐ/카테닌 길항제
WO2014092154A1 (ja) 2012-12-12 2014-06-19 株式会社ＰＲＩＳＭ Ｐｈａｒｍａ 肝線維症の予防または治療剤
EP2908822A4 (en) * 2012-10-19 2016-04-27 Prism Pharma Co Ltd TREATMENT OF HYPERPROLIFERATIVE AND PRECANCEROUS DISEASES OF THE SKIN USING A CBP / CATENIN INHIBITOR
EP2908819A4 (en) * 2012-10-19 2016-04-27 Prism Pharma Co Ltd TREATMENT OF SCLEROMERMIA USING A CBP / CATENIN INHIBITOR
US9371330B2 (en) 2010-11-16 2016-06-21 University Of Southern California Substituted pyrazino[1,2-a]pyrimidines useful as CBP/catenin antagonists for enhancing asymmetric division of somatic stem cells
EP3057590A4 (en) * 2013-10-18 2017-06-07 Hiroyuki Kouji Treatment of hepatic fibrosis using an inhibitor of cbp/catenin
EP3088401A4 (en) * 2013-12-25 2017-06-28 Eisai R&D Management Co., Ltd. (6S,9aS)-N-BENZYL-6-[(4-HYDROXYPHENYL)METHYL]-4,7-DIOXO-8-({6-[3-(PIPERAZINE-1-YL)AZETIDINE-1-YL]PYRIDINE-2-YL}METHYL)-2-(PROP-2-EN-1-YL)-OCTAHYDRO-1H-PYRAZINO[2,1-c][1,2,4]TRIAZINE-1-CARBOXAMIDE COMPOUND
CN108026104A (zh) * 2015-09-18 2018-05-11 国立大学法人鸟取大学 利用低分子化合物的癌及纤维化的抑制和再生促进的效果
US10259817B2 (en) 2015-06-23 2019-04-16 Eisai R&D Management Co., Ltd. Crystal (6S,9aS)-N-benzyl-8-({6-[3-(4-ethylpiperazin-1-yl)azetidin-1-yl]pyridin-2-yl}methyl)-6-(2-fluoro-4-hydroxybenzyl)-4,7-dioxo-2-(prop-2-en-1-yl)hexahydro-2H-pyrazino[2,1-c][1,2,4]triazine-1(6H)-carboxamide
KR20190084128A (ko) * 2010-10-07 2019-07-15 유니버시티 오브 써던 캘리포니아 체세포 줄기 세포의 비대칭 분열을 향상시키기 위한 ｃｂｐ/카테닌 길항제
WO2021086909A1 (en) 2019-10-29 2021-05-06 Eisai R&D Managment Co., Ltd. Combination of a pd-1 antagonist, a vegfr/fgfr/ret tyrosine kinase inhibitor and a cbp/beta-catenin inhibitor for treating cancer
US11369623B2 (en) 2015-06-16 2022-06-28 Prism Pharma Co., Ltd. Anticancer combination of a CBP/catenin inhibitor and an immune checkpoint inhibitor
JP2023535847A (ja) * 2020-07-16 2023-08-21 株式会社 PRISM BioLab 新規ヘテロ環化合物
WO2023215378A1 (en) * 2022-05-04 2023-11-09 Athira Pharma, Inc. Methods of treating fibrosis
US12226409B2 (en) 2017-05-16 2025-02-18 Eisai R&D Management Co., Ltd. Treatment of hepatocellular carcinoma
US12303505B2 (en) 2017-02-08 2025-05-20 Eisai R&D Management Co., Ltd. Tumor-treating pharmaceutical composition

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105061315B (zh) * 2015-08-06 2017-10-24 大连理工大学 一类1,5‑二苯基吡唑‑3‑羧酸类化合物及其应用
WO2021183791A1 (en) * 2020-03-12 2021-09-16 City Of Hope Wnt/cbp/catenin signaling pathway inhibitors and uses thereof
IL296257B2 (en) 2020-03-12 2025-06-01 3 2 Pharma Llc (6S,9aS)-8-ARYL-6-OXYBENZYL-4,7-DIOXO-2-(HETEROARYL)HEXAHYDRO-2H-PYRAZINO[2,1-c][1,2,4]TRIAZINE-1(6H)-CARBOXAMIDES AS CBP/BETA-CATENIN ANTAGONISTS
CN116925081A (zh) * 2022-04-11 2023-10-24 中国科学院上海药物研究所 一种环肽类化合物及其应用

Citations (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
WO1994003494A1 (en) 1992-08-06 1994-02-17 The Board Of Trustees Of The University Of Illinois Conformationally restricted mimetics of reverse turns and peptides containing the same
US5440013A (en) 1991-02-07 1995-08-08 The Board Of Trustees Of The University Of Illinois Conformationally restricted mimetics of beta turns and beta bulges and peptides containing the same
US5929237A (en) 1995-10-27 1999-07-27 Molecumetics Ltd. Reverse-turn mimetics and methods relating thereto
US6013458A (en) 1995-10-27 2000-01-11 Molecumetics, Ltd. Reverse-turn mimetics and methods relating thereto
WO2001000210A1 (en) 1999-06-25 2001-01-04 Molecumetics Ltd. Reverse-turn mimetics and methods relating thereto
WO2001016135A2 (en) 1999-09-01 2001-03-08 Molecumetics Ltd. Reverse-turn mimetics and methods relating thereto
US6410245B1 (en) 1998-04-01 2002-06-25 Affymax, Inc. Compositions and methods for detecting ligand-dependent nuclear receptor and coactivator interactions
US20050250780A1 (en) * 2002-10-17 2005-11-10 Myriad Genetics, Incorporated Reverse-turn mimetics and compositions and methods relating thereto
WO2005116032A2 (en) 2004-04-16 2005-12-08 Choongwae Pharma Corporation Reverse-turn mimetics and method relating thereto
US7087078B2 (en) 2000-11-21 2006-08-08 Schering Ag Tubular vascular implants (stents) and methods for producing the same
US7097850B2 (en) 2002-06-18 2006-08-29 Surmodics, Inc. Bioactive agent release coating and controlled humidity method
WO2007056513A1 (en) 2005-11-08 2007-05-18 Institute For Chemical Genomics α-HELIX MIMETICS AND METHODS RELATING TO THE TREATMENT OF FIBROTIC DISORDERS
WO2007056593A2 (en) 2005-11-08 2007-05-18 Choongwae Pharma Corporation α-HELIX MIMETICS AND METHOD RELATING TO THE TREATMENT OF CANCER STEM CELLS
WO2009051397A2 (en) * 2007-10-15 2009-04-23 Choongwae Pharma Corporation Novel compounds of reverse turn mimetics and the use thereof (3)
WO2009148192A1 (en) 2008-06-06 2009-12-10 Prism Biolab Corporation Alpha helix mimetics and methods relating thereto
WO2010044485A1 (en) 2008-10-14 2010-04-22 Prism Biolab Corporation Alpha helix mimetics in the treatment of cancer
US20100267672A1 (en) * 2009-04-15 2010-10-21 Choongwae Pharma Corporation Novel compounds of reverse-turn mimetics, method for manufacturing the same and use thereof
WO2010128685A1 (en) 2009-05-07 2010-11-11 Prism Biolab Corporation Alpha helix mimetics and methods relating thereto

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6117445A (en) * 1998-01-28 2000-09-12 Link Technology Inc. Methods for the prevention and treatment of fibrosis and sclerosis
CN100475816C (zh) * 2001-10-12 2009-04-08 中外药品株式会社 回折模拟物及其相关的方法
KR20060121842A (ko) * 2003-08-28 2006-11-29 주식회사 중외제약 β-카테닌/ＴＣＦ에 의해 활성화되는 전사의 조절
WO2006030217A2 (en) * 2004-09-15 2006-03-23 Drug Discovery Laboratory As Drug conjugates of long chain fatty acid or ester moieties as protein binding prodrugs
EP2408300B1 (en) * 2009-03-21 2016-05-11 Sunshine Lake Pharma Co., Ltd. Amino ester derivatives, salts thereof and methods of use

Patent Citations (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5440013A (en) 1991-02-07 1995-08-08 The Board Of Trustees Of The University Of Illinois Conformationally restricted mimetics of beta turns and beta bulges and peptides containing the same
WO1994003494A1 (en) 1992-08-06 1994-02-17 The Board Of Trustees Of The University Of Illinois Conformationally restricted mimetics of reverse turns and peptides containing the same
US5929237A (en) 1995-10-27 1999-07-27 Molecumetics Ltd. Reverse-turn mimetics and methods relating thereto
US6013458A (en) 1995-10-27 2000-01-11 Molecumetics, Ltd. Reverse-turn mimetics and methods relating thereto
US6410245B1 (en) 1998-04-01 2002-06-25 Affymax, Inc. Compositions and methods for detecting ligand-dependent nuclear receptor and coactivator interactions
WO2001000210A1 (en) 1999-06-25 2001-01-04 Molecumetics Ltd. Reverse-turn mimetics and methods relating thereto
WO2001016135A2 (en) 1999-09-01 2001-03-08 Molecumetics Ltd. Reverse-turn mimetics and methods relating thereto
US7087078B2 (en) 2000-11-21 2006-08-08 Schering Ag Tubular vascular implants (stents) and methods for producing the same
US7097850B2 (en) 2002-06-18 2006-08-29 Surmodics, Inc. Bioactive agent release coating and controlled humidity method
US20050250780A1 (en) * 2002-10-17 2005-11-10 Myriad Genetics, Incorporated Reverse-turn mimetics and compositions and methods relating thereto
WO2005116032A2 (en) 2004-04-16 2005-12-08 Choongwae Pharma Corporation Reverse-turn mimetics and method relating thereto
WO2007056513A1 (en) 2005-11-08 2007-05-18 Institute For Chemical Genomics α-HELIX MIMETICS AND METHODS RELATING TO THE TREATMENT OF FIBROTIC DISORDERS
WO2007056593A2 (en) 2005-11-08 2007-05-18 Choongwae Pharma Corporation α-HELIX MIMETICS AND METHOD RELATING TO THE TREATMENT OF CANCER STEM CELLS
WO2009051397A2 (en) * 2007-10-15 2009-04-23 Choongwae Pharma Corporation Novel compounds of reverse turn mimetics and the use thereof (3)
WO2009148192A1 (en) 2008-06-06 2009-12-10 Prism Biolab Corporation Alpha helix mimetics and methods relating thereto
WO2010044485A1 (en) 2008-10-14 2010-04-22 Prism Biolab Corporation Alpha helix mimetics in the treatment of cancer
US20100267672A1 (en) * 2009-04-15 2010-10-21 Choongwae Pharma Corporation Novel compounds of reverse-turn mimetics, method for manufacturing the same and use thereof
WO2010128685A1 (en) 2009-05-07 2010-11-11 Prism Biolab Corporation Alpha helix mimetics and methods relating thereto

Non-Patent Citations (190)

* Cited by examiner, † Cited by third party
Title
5 OKANAMI ET AL., GENES CELLS, vol. 1, 1996, pages 87 - 99
AGNEW, CHEM INTL. ED. ENGL., vol. 33, 1994, pages 183 - 186
ALBRANCHES ET AL., BIOTECHNOL. LETT., vol. 25, 2003, pages 725 - 30
APPENDINO, G.; MINASSI, A.; DADDARIO, N.; BIANCHI, F.; TRON, G. C., ORGANIC LETTERS, vol. 4, 2002, pages 3839 - 3841
B. RUBINFELD ET AL., SCIENCE, vol. 272, 1996, pages 1023
BAO ET AL., GYNECOL. ONCOL., vol. 7-8, 2000, pages 373 - 9
BEHRENS ET AL., NATURE, vol. 382, 1996, pages 638 - 642
BELLUSCI, S. ET AL., DEVELOPMENT, vol. 124, pages 4867 - 4878
BIENZ; CLEVERS, CELL, vol. 103, 2000, pages 311 - 20
BITAR ET AL., CELL TISSUE RES., vol. 298, 1999, pages 233 - 42
BLANC-BRUDE ET AL., NAT. MEDICINE, vol. 8, 2002, pages 987
BOROK, Z. ET AL., AM. J. RESPIR. CELL MOL. BIOL, vol. 12, 1995, pages 50 - 55
BOUVET ET AL., CANCER RES., vol. 62, 2002, pages 1534 - 40
BROWN ET AL., DIG. DIS. SCI., vol. 45, 2000, pages 1578 - 84
BUBINFELD ET AL., SCIENCE, vol. 275, 1997, pages 1790 - 1792
CADIGAN; NUSSE, GENES DEV., vol. 11, 1997, pages 3286 - 3305
CADIJAN, K.M. ET AL., GENES DEV., vol. 11, 1997, pages 3286 - 3305
CAO ET AL., CLIN. CANCER RES., vol. 5, 1999, pages 267 - 74
CARRI ET AL., INT. J. DEV. NEUROSCI., vol. 12, 1994, pages 567 - 78
CASA ET AL., CELL. GROWTH. DIFFER., vol. 10, pages 369 - 376
CHAUVET ET AL., GLIA, vol. 18, 1996, pages 211 - 23
CHILOSI, M. ET AL., AM. J. PATHOL., vol. 162, 2003, pages 1497 - 1502
CHO ET AL., PLANT MOL. BIOL., vol. 40, 1999, pages 419 - 429
CHRIVIA ET AL., NATURE, vol. 365, 1993, pages 855 - 859
CHU ET AL., NEUROSCI. LETT., vol. 343, 2003, pages 129 - 33
CLARK, JC. ET AL., AM. J. PHYSIOL., vol. 2001, pages L705 - L715
COLLINGWOOD ET AL., J. MOL. ENDOCRINOL., vol. 23, 1999, pages 255 - 275
CRAWFORD ET AL., ONCOGENE, vol. 18, 1999, pages 2883 - 2891
CRAWFORD, H.C., ONCOGENE, vol. 18, 1999, pages 2883 - 2891
DANIELS, D.L. ET AL., TRENDS BIOCHEM. SCI, vol. 26, 2001, pages 672 - 678
DANTO, S.1. ET AL., AM. J. RESPIR. CELL MOL. BIOL., vol. 12, 1995, pages 497 - 502
DASGUPTA, R.; FUCHS, E., DEVELOPMENT, vol. 126, no. 20, 1999, pages 4557 - 68
DAVIS ET AL., CANCER RES., pages 7247 - 7253
DEMIDEM ET AL., CANCER RES., vol. 61, 2001, pages 2294 - 300
DENG ET AL., EXP. NEUROL., vol. 152, 2003, pages 373 - 82
DHAL, B.D. ET AL., AM. J. PHYSIOL., vol. 269, 1995, pages L819 - L822
DINSMORE, J. AM. OSTEOPATH. ASSOC., vol. 99.9, 1999, pages L-6
ECKNER ET AL., GENES. DEV., vol. 8, 1994, pages 869 - 884
FLEISHER ET AL., ADVANCED DRUG DELIVERY REVIEWS, 1996, pages 115 - 130
FOX; ROSSOR, REV. NEURO. (PARIS, vol. 155, no. 4, 1999, pages 533 - 7
FRASER ET AL., BIOCHEM. SOC. SYMP., vol. 67, 2001, pages 89
FUCHS, E., HARVEY LECT., vol. 94, 1999, pages 47 - 48
FUJIMURO, M. ET AL., NATURE MEDICINE, vol. 9, no. 3, 2003, pages 300 - 306
FUKUNAGA ET AL., CELL TRANSPLANT, vol. 8, 1999, pages 435 - 41
GALLOP ET AL., J. MED. CHEM., vol. 37, 1994, pages 1233 - 1251
GAT ET AL., CELL, vol. 95, 1998, pages 605 - 614
GAT, U. ET AL., CELL, vol. 95, 1998, pages 605 - 614
GOFF ET AL., GENES DEV., vol. 5, 1991, pages 298 - 309
GOMEZ, M. R., BRAIN DEV., vol. 17, 1995, pages 55 - 57
GONG ET AL., PLANT MOL. BIOL., vol. 41, 1999, pages 33 - 44
GRIMINSKI ET AL., BIOTECHNOLOGY, vol. 12, 1994, pages 1008 - 1011
GRUBE, E. ET AL., HERZ, vol. 29, 2004, pages 162 - 6
GUO ET AL., CANCER RES., vol. 62, 2002, pages 4678 - 84
GURWITZ, TRENDS NEUROSCI., vol. 23, 2000, pages 386
HANAI ET AL., J. CELL BIO., vol. 158, 2002, pages 529
HAYASHI ET AL., PROC. NATL. ACAD. SCI. USA, vol. 94, 1997, pages 242 - 247
HE ET AL., CELL, vol. 99, 1999, pages 335 - 345
HE ET AL., SCIENCE, vol. 281, 1998, pages 1509 - 1512
HECHT ET AL., EMBO J., vol. 19, no. 8, 2000, pages 1839 - 1850
HIRATA; FUJISAWA, J. NEUROBIOL., vol. 32, 1997, pages 415 - 25
HOBO ET AL., PROC. NATL. ACAD. SCI. USA, vol. 96, 1999
HSIU-MING SHIU ET AL., PROC. NATL. ACAD. SCI. USA, vol. 93, November 1996 (1996-11-01), pages 13896 - 13901
HSU ET AL., MOL. CELL. BIOL., vol. 18, 1998, pages 4807 - 4818
JANKNECHT; HUNTER, NATURE, vol. 383, 1996, pages 22 - 23
JOHN D. CRISPINO ET AL., MOLECULAR CELL, vol. 3, February 1999 (1999-02-01), pages 1 - 20
JOHN M. STEWART; JANIS D. YOUNG: "Solid Phase Peptide Synthesis", 1984, PIERCE CHEMICAL COMP.
JUE, S.F. ET AL., MOL. CELL. BIOL, vol. 12, 1992, pages 321 - 328
KAPANCI, Y. ET AL., AM. J. RESPIR. CRIT. CARE MED., vol. 152, 1995, pages 2163 - 2169
KASPER, M. ET AL., HISTOL. HISTOPATHOL., vol. 11, 1996, pages 463 - 483
KATO ET AL., BRAIN RES., vol. 31, 1983, pages 143 - 7
KAWAMORITA ET AL., HUM. CELL, vol. 15, 2002, pages 178 - 82
KAWANAMI, 0. ET AL., LAB. INVEST., vol. 4-6, 1982, pages 39 - 53
KEN-ICHI TAKEMARU; RANDALL T. MOON, J. CELL. BIOL., vol. 149, no. 2, 2000, pages 249 - 254
KHALIL, N. ET AL., AM. 1. RESPIR. CELL MOL. BIOL., vol. 5, 1991, pages 155 - 162
KINZLER; VOGELSTEIN, CELL, vol. 87, 1996, pages 159 - 170
KISPERT, A. ET AL., DEVELOPMENT, vol. 122, 1996, pages 3627 - 3637
KOLLIGS ET AL., MOL. CELL. BIOL., vol. 19, 1999, pages 5696 - 5706
KOO ET AL., PROC. NATL. ACAD. SCI. USA, vol. 90, 1993, pages 4748 - 52
KOUTSOURAKIS, M. ET AL., MECH. DEV., vol. 105, 2001, pages 105 - 114
KRIL; HALLIDAY, INT. REV. NEUROBIOL., vol. 48, 2001, pages 167 - 217
KUDO ET AL., BIOCHEM. PHARMACOL., vol. 66, 2003, pages 289 - 95
KURZ ET AL., J. NEURAL TRANSM., vol. 62, 2002, pages 127 - 33
LABONTE ET AL., HEPATOL. RES., vol. 18, pages 72 - 85
LACZA ET AL., BRAIN RES. BRAIN RES. PROTOC., vol. 11, pages 145 - 54
LAM ET AL., NATURE, vol. 354, 1991, pages 82 - 84
LANDESMAN-BOLLAG, E. ET AL., ONCOGENE, vol. 20, 2001, pages 3247 - 3257
LEMERE ET AL., NEUROCHEM. RES., vol. 28, 2003, pages 1017 - 27
LEMON ET AL., CURR. OPIN. GENET. DEV., vol. 9, 1999, pages 499 - 504
LEO ET AL., GENE, vol. 245, 2000, pages 1 - 11
LI, C. ET AL., DEV. BIOL., vol. 248, 2000, pages 68 - 81
LIN, Y. ET AL., DEV. DYN., vol. 222, 2001, pages 26 - 39
LITINGTURIG, Y ET AL., NAT. GENET., vol. 20, 1998, pages 58 - 61
LU ET AL., BREAST CANCER RES. TREAT., vol. 57, 1999, pages 183 - 92
MAK, B.C. ET AL., J. BIOL. CHEM., vol. 278, no. 8, 2003, pages 5947 - 5951
MALIK ET AL., TRENDS BIOCHEM. SCI., vol. 25, 2000, pages 277 - 283
MANTEUFFEL-CYMBOROWSKA, ACTA BIOCHIM. POL., vol. 46, 1999, pages 77 - 89
MARCH, JERRY: "Advanced Organic Chemistry", 1992, JOHN WILEY & SONS
MARIN ET AL., GERIATRICS, vol. 57, 2002, pages 36 - 40
MCGREGOR ET AL., DIS. COLON. RECTUM., vol. 36, 1993, pages 834 - 9
MCKENNA ET AL., J. STEROID BIOCHEM. MOL. BIOL., vol. 69, 1999, pages 3 - 12
MCMURTRY, M.S. ET AL., J. CLIN. INVEST., vol. 115, 2005, pages 1461 - 1463
MILLER ET AL., ONCOGENE, vol. 18, 1999, pages 7860 - 7872
MILOLOZA, A. ET AL., HUM. MOL. GENET., vol. 9, 2000, pages 1721 - 1727
MIN, R. ET AL., GENES DEV., vol. 12, 1998, pages 3156 - 3161
MOLENAAR ET AL., CELL, vol. 86, 1996, pages 391 - 399
MONKLEY, S.L. ET AL., DEVELOPMENT, vol. 122, 1996, pages 3343 - 3353
MOON ET AL., TRENDS GENET., vol. 13, 1997, pages 157 - 162
MORIN ET AL., SCIENCE, vol. 275, 1997, pages 1787 - 1790
MORIN, P.J. ET AL., SCIENCE, vol. 275, 1997, pages 1787 - 1790
MORIS ET AL., PROC. NATL. ACAD. SCI. USA, vol. 93, 1996, pages 7950 - 7954
MORIS ET AL., PROC. NATL. ACAD. SCI. USA., vol. 93, 1996, pages 7950 - 7954
MOSS, J. ET AL., AM. J. RESPIR. CRIT CARE MED., vol. 163, 2001, pages 669 - 671
MOTOYAMA ET AL., NAT. GENET., vol. 20, 1998, pages 54 - 57
MULLER- SPAHN; HOCK, EUR. ARCH. PSYCHIATRY CLIN. NEUROSCI., vol. 249, no. 3, pages 37 - 42
MUNOZ-ELIAS ET AL., STEM CELLS, vol. 21, 2003, pages 437 - 48
MURAKAMI ET AL.: "The Molecular Basis of Cancer", 1995, W B SAUNDERS, article "Cell cycle regulation, oncogenes, and antineoplastic drugs", pages: 13
NILSSON ET AL., CANCER CHEMOTHER. PHARMACOL., vol. 4, no. 9, 2002, pages 93 - 100
NUSSE; VARMUS, CELL, vol. 69, 1992, pages 1073 - 1087
OGAWA ET AL., GENE, vol. 245, 2000, pages 21 - 29
ORFORD ET AL., J. CELL BIOL., vol. 146, 1999, pages 855 - 868
ORFORD ET AL., J. CELL. BIOL., vol. 146, 1999, pages 855 - 868
ORFORD ET AL., J. CELL. BIOL., vol. 146, 1999, pages B55 - 868
O'SHEA ET AL., NEURON, vol. 7, 1991, pages 231 - 7
PACHENIK ET AL., REPROD. NUTR. DEV., vol. 42, 2002, pages 317 - 26
PARR, B.A. ET AL., CURR. OPIN.. GENET. DEV., vol. 4, 1994, pages 523 - 528
PARR, B.A. ET AL., DEV. BIOL., vol. 2, no. 37, 2001, pages 324 - 332
PEIFER; POLAKIS, SCIENCE, vol. 287, 2000, pages 1606 - 1609
PELLITTERI ET AL., EUR. J. HISTOCHEM., vol. 45, 2001, pages 367 - 76
PEPICELLI, C.V., CURR. BIOL., vol. 8, 1998, pages 1083 - 1086
POLAKIS, GENES DEV., vol. 14, 2000, pages 1837 - 1851
POLAKIS, P. ET AL., ADV. EXP. MED. BIOL., vol. 47Q, 1999, pages 23 - 32
RANDOLPH ET AL., J. AM CHEM. SOC., vol. 117, 1995, pages 5712 - 14
ROBYR ET AL., MOL. ENDOCRINOL., vol. 14, 2000, pages 329 - 347
ROCCHI ET AL., BRAIN RES. BULL., vol. 61, pages 1 - 24
RODOVA ET AL., J. BIOL. CHEM., vol. 277, 2002, pages 29577
ROOSE ET AL., SCIENCE, vol. 285, 1999, pages 1923 - 1926
ROWAN ET AL., PHILOS. TRANS. R. SOC. LOND. B. BIOL. SCI., vol. 358, 2003, pages 821 - 8
RYDEL; GREENE, PROC. NATL. ACAD. SCI. USA, vol. 85, 1988, pages 1257 - 61
SAKANAKA ET AL., PROC. NATL. ACAD. SCI. USA, vol. 95, 1998, pages 3020 - 3023
SAKANAKA; WILLIAM, J. BIOL. CHEM, vol. 274, 1999, pages 14090 - 14093
SANT'ANGELO ET AL., NEUROCHEM. RES., vol. 28, 2003, pages 1009 - 15
SATA, M. ET AL., NAT. MED., vol. 8, 2002, pages 403 - 409
SATA, M., TRENDS CARDIOVASC. MED., vol. 13, 2003, pages 249 - 253
SATOH ET AL., BIOCHEM. BIOPHY5. RES. COMMUN., vol. 258, 1999, pages 50 - 3
SELMAN, M. ET AL., AM. J. PHYSIOL., vol. 279, 2000, pages L562 - L574
SHAOQIONG CHEN ET AL., J. CELL. BIOL., vol. 152, no. 1, 2001, pages 87 - 96
SHAWLER ET AL., J. IMMUNOTHER. EMPHASIS TUMOR IMMUNOL., vol. 17, 1995, pages 201 - 8
SHIKAMA ET AL., TRENDS. CELL. BIOL., vol. 7, 1997, pages 230 - 236
SHTUTMAN ET AL., PROC. NATL. ACAD. SCI. USA., vol. 11, 1999, pages 5522 - 5527
SHU, W. ET AL., DEVELOPMENT, vol. 129, 2002, pages 4831 - 4842
SIMONET, W.S. ET AL., PROC. NAT. ACAD. SCI. USA, vol. 92, 1995, pages 12461 - 12465
SIMOSA, H.F. ET AL., 1 VASE. CURG., vol. 41, 2005, pages 682 - 690
SKUBITZ ET AL., J. CELL BIOL., vol. 115, 1991, pages 1137 - 48
SMALLEY, M. J. ET AL., CANCER MET. REV., vol. 18, 1999, pages 215 - 230
SONG, D. H. ET AL., J. BIOL. CHEM., vol. 275, 2000, pages 23790 - 23797
SPRENGER-HAUSSELS ET AL., PLANT J., vol. 22, 2000, pages 1 - 8
STANLEY M. HOLLENBERG ET AL., MOLECULAR AND CELLULAR BIOLOGY, vol. 15, no. 7, July 1995 (1995-07-01), pages 3813 - 3822
STAVRIDIS; SMITH, BIOCHEM. SOC. TRANS., vol. 31, 2003, pages 45 - 9
STEIN ET AL., J. VIOL., vol. 64, 1990, pages 4421 - 4427
STOREY ET AL., FRONT VIOSCI., vol. 7, 2002, pages E155 - 84
STROVEL; SUSSMAN, EXP. CELL. RES., vol. 253, 1999, pages 637 - 648
SU ET AL., SCIENCE, vol. 262, 1993, pages 1734 - 1737
T.W. GREENE: "Protecting Groups in Organic Synthesis", 1999, JOHN WILEY & SONS, INC.
TAKAHASHI ET AL., INT. J. CANCER, vol. 85, 2000, pages 243 - 7
TAKEMARU, K. I.; MOON, R. T., J. OF CELL BIOL., vol. 149, 2000, pages 249 - 254
TAO ZHANG ET AL., CANCER RESEARCH, vol. 62, 2001, pages 8664 - 8667
TAPIA, 1C. ET AL., PROC. NAT. ACAD. SCI. U.S.A., vol. 103, 2006, pages 15079 - 84
TEBAR, R. ET AL., MECH. DEV., vol. 109, 2001, pages 437 - 440
TETSU; MCCORMICK, NATURE, vol. 398, 1999, pages 422 - 426
TSUKAMOTO, A.S. ET AL., CELL, vol. 55, 1988, pages 619 - 625
TSUNODA ET AL., ANTICANCER RES., vol. 19, 1999, pages 1149 - 52
UBAL, B.D. ET AL., AM. J. PHYSIOL., vol. 275, 1998, pages L1192 - L1199
ULMASON ET AL., PROC. NATL. ACAD. SCI. USA, vol. 96, 1999, pages 5844 - 5849
VANHEMS ET AL., EUR. J. NEUROSCI., vol. 2, 1990, pages 776 - 82
VERSTIJNEN ET AL., ANTICANCER RES., vol. 8, 1988, pages 1193 - 200
VETTER; BISHOP, CURR. BID., vol. 5, 1994, pages 168 - 78
W.L. HUNTER, ADV. DRUG DELIV. REV., vol. 58, 2006, pages 347 - 9
WAN ET AL., CHIN. MED. J., vol. 116, 2003, pages 428 - 31
WANG, G.J. ET AL., PIRTERIOSCLE.R. THROMB. VASE. BIOL., vol. 25, 2005, pages 2091 - 2087
WARBURTON, D. ET AL., MECH. DEV., vol. 92, 2000, pages 55 - 8L
WEAVER, M. ET AL., DEVELOPMENT, vol. 126, 1999, pages 4005 - 4015
WEERARATNA, A.T. ET AL., CANCER CELL, vol. 1, 2002, pages 279 - 288
WEIDENFELD, J. ET AL., J. BIOL. CHEM., vol. 277, 2002, pages 21061 - 21070
WEINER HARV. REV. PSYCHIATRY, vol. 4, 1997, pages 306 - 16
WILLERT, K. ET AL., CURR. OPIN. GENET.. DEV., vol. 8, 1998, pages 95 - 102
XIA, X. ET AL., PROC. NATL. AAD. SCI. USA, vol. 98, 2001, pages 10863 - 10868
YAMAGUCHI, T.P. ET AL., DEVELOPMENT, vol. 126, 1999, pages 1211 - 1223
YOST ET AL., GENES DEV., vol. 10, 1996, pages 1443 - 1454
ZALOOM ET AL., J. ORG. CHEM., vol. 46, 1981, pages 5173 - 76
ZHOU, L. ET AL., DEV. DYN., vol. 210, 1997, pages 305 - 314

Cited By (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102168006B1 (ko) 2010-10-07 2020-10-20 유니버시티 오브 써던 캘리포니아 체세포 줄기 세포의 비대칭 분열을 향상시키기 위한 ｃｂｐ/카테닌 길항제
KR20190084128A (ko) * 2010-10-07 2019-07-15 유니버시티 오브 써던 캘리포니아 체세포 줄기 세포의 비대칭 분열을 향상시키기 위한 ｃｂｐ/카테닌 길항제
US10092568B2 (en) 2010-11-16 2018-10-09 University Of Southern California CBP/Catenin antagonists for enhancing asymmetric division of somatic stem cells
EP2640393A4 (en) * 2010-11-16 2015-05-27 Univ Southern California ANTAGONISTS OF THE CBP / CATENIN SYSTEM FOR PROMOTING THE ASYMMETRIC DIVISION OF SOMATIC STEM CELLS
US9371330B2 (en) 2010-11-16 2016-06-21 University Of Southern California Substituted pyrazino[1,2-a]pyrimidines useful as CBP/catenin antagonists for enhancing asymmetric division of somatic stem cells
KR20130140079A (ko) * 2010-11-16 2013-12-23 유니버시티 오브 써던 캘리포니아 체세포 줄기 세포의 비대칭 분열을 향상시키기 위한 ｃｂｐ/카테닌 길항제
AU2011329854B2 (en) * 2010-11-16 2017-03-30 University Of Southern California CBP/catenin antagonists for enhancing asymmetric division of somatic stem cells
KR102077871B1 (ko) 2010-11-16 2020-02-14 유니버시티 오브 써던 캘리포니아 체세포 줄기 세포의 비대칭 분열을 향상시키기 위한 ｃｂｐ/카테닌 길항제
EP2908822A4 (en) * 2012-10-19 2016-04-27 Prism Pharma Co Ltd TREATMENT OF HYPERPROLIFERATIVE AND PRECANCEROUS DISEASES OF THE SKIN USING A CBP / CATENIN INHIBITOR
EP2908819A4 (en) * 2012-10-19 2016-04-27 Prism Pharma Co Ltd TREATMENT OF SCLEROMERMIA USING A CBP / CATENIN INHIBITOR
EP2932977A4 (en) * 2012-12-12 2016-08-10 Prism Pharma Co Ltd PREVENTIVE OR TREATMENT AGENT FOR LIVER FIBROSIS
US9700569B2 (en) 2012-12-12 2017-07-11 Prism Pharma Co., Ltd. Prevention or treatment agent for hepatic fibrosis
US10265331B2 (en) 2012-12-12 2019-04-23 Prism Pharma Co., Ltd. Prevention or treatment agent for hepatic fibrosis
WO2014092154A1 (ja) 2012-12-12 2014-06-19 株式会社ＰＲＩＳＭ Ｐｈａｒｍａ 肝線維症の予防または治療剤
EP3057590A4 (en) * 2013-10-18 2017-06-07 Hiroyuki Kouji Treatment of hepatic fibrosis using an inhibitor of cbp/catenin
EP3088401A4 (en) * 2013-12-25 2017-06-28 Eisai R&D Management Co., Ltd. (6S,9aS)-N-BENZYL-6-[(4-HYDROXYPHENYL)METHYL]-4,7-DIOXO-8-({6-[3-(PIPERAZINE-1-YL)AZETIDINE-1-YL]PYRIDINE-2-YL}METHYL)-2-(PROP-2-EN-1-YL)-OCTAHYDRO-1H-PYRAZINO[2,1-c][1,2,4]TRIAZINE-1-CARBOXAMIDE COMPOUND
US11369623B2 (en) 2015-06-16 2022-06-28 Prism Pharma Co., Ltd. Anticancer combination of a CBP/catenin inhibitor and an immune checkpoint inhibitor
US10259817B2 (en) 2015-06-23 2019-04-16 Eisai R&D Management Co., Ltd. Crystal (6S,9aS)-N-benzyl-8-({6-[3-(4-ethylpiperazin-1-yl)azetidin-1-yl]pyridin-2-yl}methyl)-6-(2-fluoro-4-hydroxybenzyl)-4,7-dioxo-2-(prop-2-en-1-yl)hexahydro-2H-pyrazino[2,1-c][1,2,4]triazine-1(6H)-carboxamide
CN108026104B (zh) * 2015-09-18 2021-06-18 国立大学法人鸟取大学 利用低分子化合物的癌及纤维化的抑制和再生促进的效果
CN108026104A (zh) * 2015-09-18 2018-05-11 国立大学法人鸟取大学 利用低分子化合物的癌及纤维化的抑制和再生促进的效果
US12303505B2 (en) 2017-02-08 2025-05-20 Eisai R&D Management Co., Ltd. Tumor-treating pharmaceutical composition
US12226409B2 (en) 2017-05-16 2025-02-18 Eisai R&D Management Co., Ltd. Treatment of hepatocellular carcinoma
WO2021086909A1 (en) 2019-10-29 2021-05-06 Eisai R&D Managment Co., Ltd. Combination of a pd-1 antagonist, a vegfr/fgfr/ret tyrosine kinase inhibitor and a cbp/beta-catenin inhibitor for treating cancer
JP2023535847A (ja) * 2020-07-16 2023-08-21 株式会社 PRISM BioLab 新規ヘテロ環化合物
EP4182317A4 (en) * 2020-07-16 2024-08-14 PRISM BioLab Co., Ltd. NEW HETEROCYCLIC COMPOUNDS
JP7689761B2 (ja) 2020-07-16 2025-06-09 株式会社 PRISM BioLab 新規ヘテロ環化合物
WO2023215378A1 (en) * 2022-05-04 2023-11-09 Athira Pharma, Inc. Methods of treating fibrosis

Also Published As

Publication number Publication date
EP2678341A1 (en) 2014-01-01
CN103517904A (zh) 2014-01-15
JP2014509298A (ja) 2014-04-17
US20140051706A1 (en) 2014-02-20

Similar Documents

Publication Publication Date Title
US20140051706A1 (en) Alpha helix mimetics and methods relating thereto
EP2303887B1 (en) Alpha helix mimetics and methods relating thereto
CN102482258B (zh) α-螺旋模拟物和与其相关的方法
JP5545573B2 (ja) アルファへリックスミメティック及び関連の方法
BRPI0509888B1 (pt) Compostos miméticos de direção inversa, composição farmacêutica e usos terapêuticos dos mesmos
HK1190401A (en) Alpha helix mimetics and methods relating thereto
HK1156030B (en) Alpha helix mimetics and methods relating thereto
HK1171440B (en) Alpha helix mimetics and methods relating thereto

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12710567

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2013539024

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

REEP Request for entry into the european phase

Ref document number: 2012710567

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2012710567

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 14001470

Country of ref document: US